Neuropathix, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing a patented product platform of novel molecules from our proprietary socially responsible pain management therapeutics to treat patients with a variety of unmet medical needs. Since 2010, we have been principally involved in the research and development of synthetic cannabidiol (“CBD”) therapeutics through pre-clinical drug discovery and development processes. We have developed our own intellectual property portfolio and established relationships with globally recognized third parties who are considered leaders in active pharmaceutical (“API”) contract manufacturers, formulators and contract bulk drug manufacturers. From 2012 to 2019, the Neuropathix subsidiary Kannalife Sciences, Inc. held an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife has also developed its own patented molecules lead by KLS-13019 called by Sports Illustrated as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.”
As a licensee of the ‘507 Patent, Kannalife believes these NIH-OTT licenses have given the Company a significant preclinical lead time to evaluate both HE and CIPN and that this preclinical research has led to an advanced drug development program regarding a broader range of novel CBD based therapeutics with a long IP life and without competition that focuses on neurodegenerative and oxidative stress related diseases.
After careful pre-clinical evaluation of CBD, and understanding its PK/PD limitations, we began the process of new target drug candidate discovery. In 2015 we developed, tested in pre-clinical settings and patented an estate of cannabidiol-like NCE’s lead by KLS-13019 that significantly improved on the limitations of cannabidiol, focusing on increased bioavailability, potency and safety. Currently the following Patents have been granted including 2 in the U.S. (#9611213 & #10004722), Japan JP6486950B2, Russia Patent RU2676475C2, China CN106456573B, Australia AU2015204609B2, Canada CA2936506A1 and the following territories in Europe (AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, LU, MC, NL, SE and TR) as well as the European Union EP3094318B1; this intellectual property is currently pending patent approval in Brazil and India.
In December 2017, Kannalife received a grant from National Institute on Drug Abuse (NIDA) to compare CBD and our novel molecule KLS-13019 for its development in Chemotherapy Induced Peripheral Neuropathy and Drug Dependence. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain and affects approximately 1/3 of patients undergoing chemotherapy cancer treatment. KLS-13019 can also be valuable as a potential alternative for opioid pain management.
Neuropathix is currently conducting research and development of our proprietary therapeutic platform at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for targeted drug candidates to treat Hepatic Encephalopathy (“HE”), Traumatic Brain Injury (“TBI”), Chronic Traumatic Encephalopathy (“CTE”), Radiation Dermatitis (“RD”) and Chemotherapy Induced Peripheral Neuropathy (“CIPN”).
We are one of the leading companies focused on addressing neurodegenerative, oxidative Stress and neuropathic pain related diseases and related social issues: cannabis as a medicament, concussion related injuries like TBI and CTE, cancer treatment, neuropathic pain and the opioid crisis.